anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Health disparities between White and Black, Indigenous and People of Color (BIPOC) are well documented in the United States; this phenomenon is driven in part by discrimination experiences and is an important contributor to well-being and functioning, including among military service members and Veterans. The chronic stress of racism has both psychological and physiological effects. Discrimination is associated with increased psychological distress, including higher rates of PTSD among Veterans of Color (VOC), poorer health behavior and decreased healthcare utilization. Race-based stress is also linked to increased allostatic load (AL), which is a measurable index of wear-and-tear on the body due to chronic stress exposure that is associated with greater disease burden and mortality. Recognizing the unmet need for interventions to help VOC process and cope with experiences of discrimination, the Race-based Stress/Trauma and Empowerment (RBSTE) intervention (Carlson, Endsley, Motley, Shawahin, \& Williams, 2018) was developed. RBSTE is a group-based approach that combines cultural adaptations of established psychotherapeutic techniques with novel strategies to foster resilience and empowerment for VOC. Initial qualitative data suggests the promise of this approach, but no systematic data are yet available to determine whether or not RBSTE is achieving its goals of enhancing coping and restoring well-being. The proposed project is a pilot randomized controlled trial (RCT) with multi-modal longitudinal assessment. Participants will be recruited from VA facilities and the surrounding community. VOC who report race-based stress, with minimal exclusions, will be evaluated at baseline, randomized in groups to one of two wellness interventions and then re-evaluated immediately after treatment. The interventions include RBSTE and Present Centered Therapy (PCT), designed to control for nonspecific aspects of RBSTE, including support and participation in an all-BIPOC group. The interventions will be delivered in 8 weekly 90-minute group sessions by a trained mental health professional using videoconferencing. The aims of the project are (1) to assess the feasibility of recruiting VOC for an RCT of this nature; (2) to examine the acceptability and appropriateness of intervention content, the feasibility of participation, and participant's perceptions of provider behavior and attitudes; and (3) to establish the optimal strategy for quantifying mental and physical health outcomes for future studies. Thus, the project will set the stage for evaluation of RBSTE's efficacy and ultimately implementation. This critically important program of research will provide guidance as to best practices for the management of race-based stress, with the ultimate goal of eliminating health disparities for Veterans and the community more broadly.
<P>PROBLEM TO BE SOLVED: To provide a method of manufacturing improved keratin which can suitably perform application to a cosmetic, a medical product or the like.  <P>SOLUTION: The method of manufacturing improved keratin includes the followings. The keratin as a raw material added with a mineral is fermented, subsequently the fermentation keratin is mixed with an organic acid and is ripened. Concretely, the raw material keratin is added with a mineral and steamed by sanitized water of a prescribed amount, then is added with aspergillus or the like and is fermented. The fermentation keratin is mixed with an organic acid mixture of citric acid or the like which has a carboxyl group, is held at a predetermined temperature, is ripened, and is filtration-extracted. According to the method of manufacturing, as for a dispersion liquid of the raw material keratin, an oxygen bond is cut by a fermentation action of aspergillus or the like, further a bivalent mineral suitably combines with a monomer unit terminal of the cut keratin and the status is held, thereby the keratin which can be applied to a cosmetic, a medical product or the like can be efficiently manufactured by a low molecular weight compared with conventional one.  <P>COPYRIGHT: (C)2010,JPO&INPIT
1,160,640. Anti-caries compositions. PROCTER & GAMBLE CO. 29 Dec., 1967 [29 Dec., 1966], No. 59117/67. Heading A5B. [Also in Division C2] An oral composition for caries prophylaxis comprises:-(a) at least one water-soluble fluoride in a quantity sufficient to provide from 25 to 4000‹ parts of fluoride ions per million parts by weight of the composition, and (b) from 0.05% to 5.0% by weight of at least one distannous salt of a gem-diphosphonic acid having the formula:- wherein R 1  is hydrogen, halogen, hydroxyl, benzyl, alkyl, hydroxyalkyl, methoxyalkyl or carboxyalkyl and has up to 12 carbon atoms and R 2  is hydrogen, halogen, hydroxyl, acetyl, phenyl, benzyl, alkyl, hydroxyalkyl, methoxyalkyl or carboxyalkyl and has up to 12 carbon atoms. Many distannous diphosphonates are specified, distannous methanoediphosphonate and distannous ethane-1-hydroxy-1,1-diphosphonate being preferred. The water-soluble fluoride may be an inorganic fluoride, an amine hydrofluoride, a hydroxyalkyl alkyl anarnonium fluoride of specified type or an addition compound of an amino acid and an hydrofluoric acid or a fluoride. The preferred fluoride is stannous fluoride used in a quantity sufficient to provide a total amount of at least 300 parts per million of stannous tin. The pH of the compositions is suitably between 2.5 and 7. Other usual components of dentrifices and mouthwashes may be present e.g. abrasive materials, sudsing agents, binders, humectants, flavouring and sweetening materials, and in the case of toothpaste, a thickening material e.g. water-soluble salts of cellulose ethers, natural gums, colloidal magnesium aluminium silicate or finely divided silica are generally added.
A method, computer program product, and computing system for receiving a notification that a patient has arrived to a telehealth session before the telehealth session begins. The notification is received via a computing device. In response to receiving the notification that the patient has arrived to the telehealth session before the telehealth session begins, information associated with the patient is automatically pulled by a virtual assistant. The patient is prompted by the virtual assistant to complete a task before the telehealth session begins. A question is received from the patient before the telehealth session begins. Patient data may be obtained from one or more sources. The obtained patient data is processed to determine if the patient data is indicative of a possible medical condition and the medical condition is provided to a medical professional. An answer to the question is provided. The answer is personalized to the patient.
Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
This is a population-based, genetic-association, candidate polymorphism study. It will involve a prospective and a retrospective component. A blood draw or saliva sample will be performed during the participant's admission to BCPP, which may occur at any point during the participant's length of stay. When a participant has been deemed 'Ready for Discharge' by his/her attending psychiatrist at BCPP, a full phenotype will be obtained via retrospective chart review. Genetic analyses and determination of protein levels will be performed after chart review. Following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.
The present invention relates to an extract of Agarum clathratum subsp. yakishiriense Yamada ex G.H. Boo & P.C. Silva, which is a seaweed, a fraction thereof, and an isolated compound thereof for treatment and prevention of hearing loss. The extract derived from Agarum clathratum subsp. yakishiriense Yamada ex G.H. Boo & P.C. Silva, the fraction thereof, and monogalactosylmonoacylglycerol, which is an isolated compound thereof are derived from a natural product and are not toxic and safe to a human body. In addition, the extract, the fraction thereof, and the compound thereof of the present invention exhibit a protective effect on an auditory hair cell in various zebrafish animal models of hearing loss, and can be effectively applied to the prevention and treatment of hearing loss without a side effect.
BACKGROUND Indirect muscle injuries (IMIs) are a considerable burden to elite football (soccer) teams and prevention of these injuries offers many benefits. Preseason medical, musculoskeletal and performance screening (termed periodic health examination (PHE)) is used to help determine players at risk of injuries such as IMIs, where identification of PHE-derived prognostic factors (PF) may inform IMI prevention strategies. Furthermore, using several PFs in combination within a multivariable prognostic model may allow individualised IMI risk estimation and specific targeting of prevention strategies, based upon an individual's PF profile. No such models have been developed in elite football and the current IMI prognostic factor evidence is limited. This study aims to: 1) to develop and internally validate a prognostic model for individualised IMI risk prediction during a season in elite footballers, using the extent of the prognostic evidence and clinical reasoning; 2) explore potential PHE-derived PFs associated with IMI outcomes in elite footballers, using available PHE data from a professional team.

METHODS A retrospective review has been completed of PHE and injury data, routinely collected over 5 years (from 1st July 2013 to 19th May 2018) from a population of elite male players at an English Premier League football club. Of 60 candidate PFs, 15 were excluded. Ten factors will be included in model development, identified from a systematic review, missing data assessment, measurement reliability evaluation and clinical reasoning. A full multivariable logistic regression model will be fitted, to ensure adjustment before backward elimination. The performance and internal validation of the model will be assessed. The remaining 35 candidate PFs are eligible for further exploration, using univariable logistic regression to obtain unadjusted risk estimates. Exploratory PFs will be grouped according to type and incorporated into multivariable logistic regression models to determine risk estimates.

DISCUSSION This study will offer insights into clinical usefulness of a model to predict IMI risk in elite football and highlight the practicalities of model development in this setting. Exploration may identify other relevant PFs for future confirmatory studies, model updating, or influence future injury prevention research.
Generally, fasting and refeeding confer anti- and proinflammatory effects, respectively. In humans, these caloric-load interventions function, in part, via regulation of CD4+ T cell biology. However, mechanisms orchestrating this regulation remain incomplete. We employed integrative bioinformatics of RNA sequencing and high-performance liquid chromatography-mass spectrometry data to measure serum metabolites and gene expression of peripheral blood mononuclear cells isolated from fasting and refeeding in volunteers to identify nutrient-load metabolite-driven immunoregulation. Propionate, a short chain fatty acid (SCFA), and the SCFA-sensing G protein-coupled receptor 43 (ffar2) were coordinately and inversely regulated by fasting and refeeding. Propionate and free fatty acid receptor agonists decreased interferon-γ and interleukin-17 and significantly blunted histone deacetylase activity in CD4+ T cells. Furthermore, propionate blunted nuclear factor κB activity and diminished interleukin-6 release. In parallel, propionate reduced phosphorylation of canonical T helper 1 (TH1) and TH17 regulators, STAT1 and STAT3, respectively. Conversely, knockdown of free fatty acid receptors significantly attenuated the anti-inflammatory role of propionate. Interestingly, propionate recapitulated the blunting of CD4+ TH cell activation in primary cells from obese individuals, extending the role of this metabolite to a disease associated with low-grade inflammation. Together, these data identify a nutrient-load responsive SCFA-G protein-coupled receptor linked pathway to regulate CD4+ TH cell immune responsiveness.
PURPOSE: To obtain an orally administrable pharmaceutical formulation containing raloxifene, its ester, ether or salt and a hydrophilic carrier composition and useful for the anti-estrogen or anti-androgen therapy, etc. CONSTITUTION: This formulation can be produced by using raloxifene, its ester, ether or salt in combination with a surfactant (e.g. polysorbate 80) and a water- soluble diluent (e.g. lactose) as essential components and optionally compounding the above components with a hydrophilic binder (e.g. polyvinyl pyrrolidone), a lubricant, a disintegrant, etc. It can be formed in the form of tablet, capsule, etc., by conventional method and the tablet may be coated with a film. Raloxifene is useful also for the treatment of osteoporosis of postmenopausal women.
BACKGROUND: The clinical features of Multisystem Inflammatory Syndrome in Children (MIS-C) have been well documented, but there is limited data regarding the short term and longitudinal outcomes of children living in rural areas. We report the demographic and clinical features, as well as the multi-specialty follow-up of patients with MIS-C served by a large tertiary care rural health system.
METHODS: Patients that met the Centers for Disease Control (CDC) case definition of MIS-C admitted between March 1, 2020, and March 31, 2021, were included in this case series. Manual chart review was used to report demographic characteristics, clinical, laboratory and radiologic features during acute hospitalization and multispecialty follow-up, and adherence to follow-up 6-10 weeks after hospital discharge.
RESULTS: Twenty-one patients with MIS-C were admitted at our center during the review period. Ninety percent of the cohort required intensive care during hospitalization. Of 19 patients with measured ejection fractions, 52 % had some degree of left ventricular dysfunction on admission; nine patients had electrocardiogram changes on admission. The majority of patients had elevated inflammatory markers during hospitalization. Most patients had resolution of symptoms, improvement in inflammatory markers, and normal cardiac function at the time of discharge. Follow-up with pediatric cardiology, hematology-oncology and infectious disease was indicated for most patients at discharge. Of these, 100 % of patients kept initial follow-up appointments with pediatric cardiology and infectious disease, while 94 % kept initial follow-up appointments with pediatric hematology-oncology.
CONCLUSION: Though most patients were critically ill during hospitalization, the majority had resolution of cardiac abnormalities and inflammatory markers at discharge and timely follow-up with multiple subspecialists after admission with MIS-C.
The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistant/-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Karenitecin analogues, including but not limited to, Germanium-substituted Karenitecin, Deuterated Karenitecin, and “flipped” E-ring Karenitecin, are disclosed and claimed. In addition, Karenitecin and one or more cancer treating agents administered either concomitantly or in series via oral and/or i.v. means, are also disclosed and claimed. Methods for the administration of Karenitecin to: (i) increase Progression Free Survival (PFS); (ii) increase the platinum-free time interval; (iii) decrease CA-125 marker levels; and (iv) mitigate or prevent chemotherapeutic drug-resistance from developing are disclosed and claimed herein. Methods for the use of Karenitecin to treat advanced solid tumors; refractory or recurrent solid tumors; recurrent malignant glioma; primary malignant glioma; persistent or recurrent epithelial ovarian or primary peritoneal carcinoma; and other identified cancer types are also disclosed and claimed.
FIELD: stomatology. SUBSTANCE: new dental paste is made on the basis of bioactive substances combination. Paste has mineral-vitamin laminaria concentrate, lipid complex of senna and phytin, chlorophyll, carotinoids, trace and macroelements, tocopherol that provide curative-prophylactic effect. Also, paste has preparations improving teeth cleansing and dissolving dental stone, and special preserving agent. Paste using: teeth cleansing (every day, twice, for 3 min), application on teeth and gums (for 5-7 min before sleeping). EFFECT: enhanced effectiveness of paste (healing, antiinflammatory, hemostatic actions, caries prevention, improved mineralization and others). 3 tbl
Permanent molar teeth meeting the inclusion criteria will be included into the study. Following local anaesthesia and dental dam application, caries excavation will be performed; and after exposure, the pulp will be amputated to the level of the canal orifices (full pulpotomy) using a sterile high-speed round bur under water coolant. After haemostasis is achieved, Mineral trioxide aggregate (MTA) will be gently placed over the pulp to a thickness of 2-3 mm and the tooth will be restored using glass ionomer cement and composite resin. A postoperative periapical radiograph will be taken. Patients will be reviewed at 6., 12., 24. and 36. months for clinical and radiographical success. The data will be analysed statistically using chi square test.
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
248 women with the history of implantation failure volunteered to receive PBMC-therapy. After immunologic consultation and doing flow cytometry analysis, 100 women with at least three IVF/ET failure who had low Th-17/Treg ratio in comparison with healthy control were enrolled in this study. These 100 patients divided randomly into two groups, 50 patients received PBMC and 50 patients as the control group received PBS. PBMCs were obtained from patients themselves five days before embryo transfer (ET) and were cultured with hCG for 48 hours. Frothy-eight hours later, PBMCs were then administered into the uterine cavity of that patient from the study group two days before ET. PBS was inseminated into the uterine cavity of the control group instead of PBMC. The concentration of inflammatory cytokines was examined in the supernatant of cultured PBMCs 2, 24 and 48 hour after incubation by ELISA. The pregnancy occurrence was confirmed 12 days after ET through positive pregnancy test (β-hCG test). The success of implantation and the occurrence of clinical pregnancy were evaluated by ultrasound through the observation of the number and the location of gestational sacs at 5-6 weeks and confirming the embryo heart pulsation.
This is a prospective comparative randomized study. 56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality. The amount of blood loss during the entire process was measured. The score of pain was evaluated using the NRS rating scale. Sedation score through Ramsey sedation score. The time required for the first requirement of analgesia was also recorded as well as intraoperative and postoperative problems.
Delirium is a complex neuropsychiatric syndrome with sudden change in cognition such as disturbance in orientation or memory particularly in elderly patients in the context of acute illness. Multiple complications such as falls or increased duration of hospitalisation may result in delirium. Long-term consequences may result in increased mortality rates and higher admissions rates to nursing homes. In 2012, delirium prevalence in the Emergency Department (ED) of the University Hospital Basel was 9.5% in patients with 65 years and over. Although a systematic delirium management was introduced in 2012, without systematic screening delirium detection rates varies between 20 and 40% only. The risk of non-detection over the complete hospitalisation is high when early delirium detection did not occur in the ED. In a preliminary evaluation we could show the usefulness of the mCAM-ED
<P>PROBLEM TO BE SOLVED: To provide a body hair treatment apparatus and a treatment material for use therewith capable of preventing the adherence of the treatment material without causing a clogging within a treatment material supply part, stably discharging the treating material, refreshing users in use, restraining irritation and preventing the skin from becoming rough.  <P>SOLUTION: The body hair treatment apparatus has a body hair treatment part 6 to perform a cutting treatment or depilatory treatment of body hairs. Further, in the vicinity of the body hair treatment part 6, it has a treatment material supply part to discharge a treatment agent for treating body hairs. The treatment material mainly comprises lower alcohols and water. The composition of the treatment material is entirely composed of volatile ingredients or liquid-like ingredients.  <P>COPYRIGHT: (C)2003,JPO
Using in vitro adhesion of recombinant rat L-selectin-Ig or rat neutrophils, it has been demonstrated that these materials bind to sulfatide that has been present in solid phase on a plastic surface. The binding activity appears to have structural requirements, with the sulfate group being critically present in position 3 on the pyranose ring of galactose. When used in vivo, it has been demonstrated that sulfated glycolipids such as brain sulfatide and ganglioside, have significantly protective effects in two models of lung inflammation, the first systemic activation of complement and the second occurring after intrapulmonary deposition of immune complexes. Both inflammatory reactions are complement, neutrophil and selectin-dependent. The protective effects of these compounds are linked to their ability to prevent the recruitment of neutrophils into lung tissue. On the basis of these findings, it is demonstrated by sulfatides and related compounds have significant in vivo anti-inflammatory activities. These compounds thus represent a new class of anti-inflammatory agents.
Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.